Abstract:Simultaneous inhibition of both tumor growth and metastasis is the key to treating metastatic cancer, yet the development of effective drug delivery systems represents a great challenge since multimodal therapeutic agents must be rationally combined to overcome the biological mechanisms underpinning tumor cell proliferation and invasion. In this context, we report a hybrid therapeutic nanoscale platform that incorporates an anti-proliferative drug, doxorubicin (DOX), and an anti-NF-κB agent, p65-shRNA, for effective treatment of metastatic breast cancer. In our design, we first conjugated DOX via an acid-labile linker onto gold nanorods that were pre-modified with the tumor targeting peptide RGD and a positively charged, disulfide cross-linked short polyethylenimines (DSPEI), and then incorporated shRNA through electrostatic complexation with DSPEI. We show that this "all in one" nanotherapeutic system (RDG/shRNA@DOX) can be effectively internalized through RGD-mediated endocytosis, followed by stimuli-responsive intracellular co-release of DOX and shRNA. Our in vitro experiments suggest that this multimodal system can significantly inhibit cell proliferation, angiogenesis, and invasion of metastatic MDA-MB-435 cancer cells. Systemic administration of RDG/shRNA@DOX into a metastatic mouse model led to enhanced tumor accumulation, and, most importantly, significant inhibition of in situ tumor growth and almost complete suppression of tumor metastasis. We believe this hybrid multimodal nanotherapeutic system provides important insight into the rational design of therapeutic systems for the effective treatment of metastatic carcinoma.STATEMENT OF SIGNIFICANCE:The key to successfully treat metastatic cancer is the simultaneous inhibition of both tumor growth and metastasis. This represents a great challenge for the design of drug delivery systems since multimodal therapeutic agents must be rationally combined to overcome the respective biological mechanisms underpinning tumor cell proliferation and invasion. Toward this end, we developed a hybrid nanomedicine platform that incorporates an anti-proliferative drug, doxorubicin (DOX), and an anti-NF-κB agent, p65-shRNA, for effective treatment of metastatic breast cancer. We showed that this multimodal system (RDG/shRNA@DOX) enhanced tumor accumulation, led to prolonged circulation, and most importantly, significant inhibition of in situ tumor growth and almost complete suppression of tumor metastasis. We believe this hybrid multimodal nanotherapeutic system provides significant insight into the rational design of therapeutic systems for the effective treatment of metastatic cancer.

Targeting High Expressed Alpha(5)Beta(1) Integrin In Liver Metastatic Lesions To Resist Metastasis Of Colorectal Cancer By Rpm Peptide-Modified Chitosan-Stearic Micelles

Synthesis and biological application of BKT-140 peptide modified polymer micelles for treating tumor metastasis with an enhanced cell internalization

Enhanced Antitumor and Anti-Metastasis Efficiency Via Combined Treatment with Cxcr4 Antagonist and Liposomal Doxorubicin

Integrin αvβ3-targeted liposomal drug delivery system for enhanced lung cancer therapy

Suppress Orthotopic Colon Cancer and Its Metastasis Through Exact Targeting and Highly Selective Drug Release by a Smart Nanomicelle.

Rgd Peptide Conjugated Liposomal Drug Delivery System for Enhance Therapeutic Efficacy in Treating Bone Metastasis from Prostate Cancer

Optimization Of Transforming Growth Factor-Beta 1 Sirna Loaded Chitosan-Tripolyphosphate Nanoparticles For The Treatment Of Colorectal Cancer Hepatic Metastasis In A Mouse Model

Multifunctional Self-Delivery Micelles Targeting the Invasion-Metastasis Cascade for Enhanced Chemotherapy Against Melanoma and the Lung Metastasis

Co-targeting of DNA, RNA, and Protein Molecules Provides Optimal Outcomes for Treating Osteosarcoma and Pulmonary Metastasis in Spontaneous and Experimental Metastasis Mouse Models

RGD Peptide-Mediated Chitosan-Based Polymeric Micelles Targeting Delivery for Integrin-Overexpressing Tumor Cells.

A Novel Mitochondrial Targeted Hybrid Peptide Modified HPMA Copolymers for Breast Cancer Metastasis Suppression.

A Novel Nanomissile Targeting Two Biomarkers And Accurately Bombing Ctcs With Doxorubicin

The use of a tumor metastasis targeting peptide to deliver doxorubicin-containing liposomes to highly metastatic cancer.

Investigation of the enhanced antitumour potency of CD46-specific chimeric antigen receptor-T cells in human colorectal cancer liver metastases after combination with nanotherapeutics

Rational Design of Multimodal Therapeutic Nanosystems for Effective Inhibition of Tumor Growth and Metastasis.

Somatostatin Octapeptide Inhibits Cell Invasion and Metastasis in Hepatocellular Carcinoma Through PEBP1

A Liposome-Based Combination Strategy Using Doxorubicin and a PI3K Inhibitor Efficiently Inhibits Pre-Metastatic Initiation by Acting on Both Tumor Cells and Tumor-Associated Macrophages

Study on the Inhibitory Effect of Small Tripeptide CMS024 on Tumor Growth and Metastasis in Nude Mice Model of Human Hepatocellular Carcinoma Metastasis

Functional Imaging and Targeted Drug Delivery in Mice and Patient Tumors with a Cell Nucleolus-Localizing and Tumor-Targeting Peptide.

Tumor Cells-Specific Targeting Delivery Achieved by A54 Peptide Functionalized Polymeric Micelles

A Core-Satellite Micellar System Against Primary Tumors and Their Lymphatic Metastasis Through Modulation of Fatty Acid Metabolism Blockade and Tumor-Associated Macrophages